Astradsson Arnar, Cooper Oliver, Vinuela Angel, Isacson Ole
NINDS Udall Parkinson's Disease Research Center of Excellence, Harvard University and McLean Hospital, Belmont, Massachusetts 02478, USA.
Neurosurg Focus. 2008;24(3-4):E6. doi: 10.3171/FOC/2008/24/3-4/E5.
In this review, the authors discuss recent advances in the field of cell therapy for Parkinson disease (PD). They compare and contrast recent clinical trials using fetal dopaminergic neurons. They attribute differences in cell preparation techniques, cell type specification, and immunosuppression as reasons for variable outcome and for some of the side effects observed in these clinical trials. To address ethical, practical, and technical issues related to the use of fetal cell sources, alternative sources of therapeutic dopaminergic neurons are being developed. The authors describe the progress in enrichment and purification strategies of stem cell-derived dopaminergic midbrain neurons. They conclude that recent advances in cell therapy for PD will create a viable long-term treatment option for synaptic repair for this debilitating disease.
在这篇综述中,作者讨论了帕金森病(PD)细胞治疗领域的最新进展。他们比较并对比了近期使用胎儿多巴胺能神经元的临床试验。他们将细胞制备技术、细胞类型规格和免疫抑制方面的差异归因于这些临床试验中结果的差异以及所观察到的一些副作用的原因。为了解决与使用胎儿细胞来源相关的伦理、实际和技术问题,正在开发治疗性多巴胺能神经元的替代来源。作者描述了干细胞衍生的多巴胺能中脑神经元富集和纯化策略的进展。他们得出结论,PD细胞治疗的最新进展将为这种使人衰弱的疾病的突触修复创造一种可行的长期治疗选择。